A bill to amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.
About This Bill
Committee
Latest Action · February 6, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.